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Background. Early identiﬁcation of pathogens from blood cultures using matrix-assisted laser desorption ion-
ization time-of-ﬂight (MALDI-TOF) mass spectrometry may optimize the choice of empirical antibiotic therapy
in the setting of bloodstream infections. We aimed to assess the impact of this new technology on the use of
antibiotic treatment in patients with gram-negative bacteremia.
Methods. We conducted a prospective observational study from January to December 2010 to evaluate the
sequential and separate impacts of Gram stain reporting and MALDI-TOF bacterial identiﬁcation performed on
blood culture pellets in patients with gram-negative bacteremia. The primary outcome was the impact of MALDI-
TOF on empirical antibiotic choice.
Results. Among 202 episodes of gram-negative bacteremia, Gram stain reporting had an impact in 42 cases
(20.8%). MALDI-TOF identiﬁcation led to a modiﬁcation of empirical therapy in 71 of all 202 cases (35.1%), and
in 16 of 27 cases (59.3%) of monomicrobial bacteremia caused by AmpC-producing Enterobacteriaceae. The most
frequently observed impact was an early appropriate broadening of the antibiotic spectrum in 31 of 71 cases
(43.7%). In total, 143 of 165 episodes (86.7%) of monomicrobial bacteremia were correctly identiﬁed at genus
level by MALDI-TOF.
Conclusions. In a low prevalence area for extended spectrum betalactamases (ESBL) and multiresistant gram-
negative bacteria, MALDI-TOF performed on blood culture pellets had an impact on the clinical management of
35.1% of all gram-negative bacteremia cases, demonstrating a greater impact than Gram stain reporting. Thus,
MALDI-TOF could become a vital second step beside Gram stain in guiding the empirical treatment of patients
with bloodstream infection.
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Matrix-assisted laser desorption ionization time-of-
ﬂight (MALDI-TOF) mass spectrometry (MS), formerly
conﬁned to research laboratories, has emerged as a
recent revolution in clinical microbiology [1]. For bac-
terial identiﬁcation, this technology compared fa-
vorably with the classical phenotypical methods in
bacteriology in terms of time to result, accuracy, ease
of use, and cost-effectiveness [2, 3]. Due to the speed of
this technology, MALDI-TOF was very soon applied
to identify microorganisms detected in blood cultures
[4–6], because an appropriate antibiotic therapy cover-
ing the etiological agent is of paramount importance
in decreasing mortality of bacteremic patients with
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sepsis [7, 8]. In the setting of bloodstream infections, MALDI-
TOF applied to bacterial pellet obtained from positive blood
culture is allowing a rapid identiﬁcation of around 80% of
pathogens. This identiﬁcation is accurate in ≥99% of cases
[4–6]. Identiﬁcation of gram-negative pathogens has been
shown to be very reliable, although the success rate is lower for
gram-positive bacteria (mainly streptococci) and for encapsu-
lated bacteria such as Klebsiella pneumoniae and Haemophilus
inﬂuenzae [4–6].
In clinical practice, the microbiology laboratory has an
impact on the management of bloodstream infections at ﬁrst
by reporting the results of positive blood cultures. Munson
et al demonstrated that the Gram stain result reported by tele-
phone to the clinician had an even greater inﬂuence on the
antibiotic regimen than antimicrobial susceptibility testing [9].
A same-day transmission of MALDI-TOF MS–based identi-
ﬁcation of the pathogen isolated from blood cultures would
obviously represent another opportunity to increase the appro-
priateness of empirical antibiotic therapy. Although this strategy
is theoretically promising, very few data are available analyzing
the routine use of MALDI-TOF in this setting [10, 11].
The aim of our study was thus to assess the impact of
MALDI-TOF on the clinical management of gram-negative
bacteremia. We prospectively performed MALDI-TOF MS-
based bacterial identiﬁcation on blood culture pellets immedi-
ately after Gram stain reporting [5] and assessed the impact of
this procedure on antimicrobial treatment.
METHODS
Design and Case Deﬁnition
This prospective observational study was conducted between
January and December 2010 in the University Hospital of
Lausanne, an 850-bed primary and tertiary care hospital in
Western Switzerland. Patients with a ﬁrst episode of gram-
negative bacteremia (including polymicrobial infections) for
whom an infectious disease (ID) consultation was performed
were included (Figure 1). Data on successive antibiotic thera-
pies were prospectively assessed by the clinical microbiologist
when reporting the results to the clinicians using a standard-
ized case report form (CRF). The sequence of antibiotic pre-
scription was checked using the ID consultation report and a
ﬁnal CRF was ﬁlled in to include standardized clinical and ep-
idemiological data. The impact of the Gram stain (ﬁrst step)
and the MALDI-TOF reporting (second step) on the antimi-
crobial management were assessed by 2 ID specialists
(O. C. and G. G.) as described below. The primary outcomes
were the respective and separate impacts of each step on the
empirical antibiotic therapy. The design of this study was in
accordance with the ethical standards of our local ethics
committee.
Routine Procedures
Positive blood cultures were detected by the BACTEC 9240
automated blood culture system (Becton Dickinson, Sparks,
MD). The microbiology laboratory ran daily from 8 AM to 5
PM. Gram stain was immediately performed on all positive
blood cultures during this period and early the next morning
when the blood cultures became positive overnight. Direct
MALDI-TOF has been routinely performed in our center
since September 2009 on all positive blood cultures immedi-
ately after the Gram staining. According to local procedure,
pellets from positive blood cultures were prepared as described
by Prod’hom et al [5] during the same day when bacterial
growth was detected before 5 PM. Under these circumstances,
Gram stain reporting was followed about 1 hour later by a
second call to the clinician in charge of the patient in order to
transmit the MALDI-TOF-based identiﬁcation.
Mass spectra were acquired on a Microﬂex LT MALDI-TOF
(Bruker Daltonics, Bremen, Germany). Spectral analysis and
comparison with the database were performed using MALDI
BioTyper 2.0 software. According to the criteria proposed by
the manufacturer, an identiﬁcation was considered reliable at
the species level when the score value was x≥ 2 and at the
genus level when the score was 1.7≤ x < 2. Blood culture
results were transmitted by clinical microbiologists directly to
the clinicians and during a daily meeting to ID consultants.
ID consultations were requested by clinicians in charge of the
patients.
Hospital Setting
The incidence of gram-negative bacteria producing extended
spectrum betalactamases (ESBL) was low according to the
hospital microbiology database (<5% of all gram-negative
bacilli). Similarly, community-associated ESBL-producing Es-
cherichia coli remained rare in 2010 (3.4%, source: www.
anresis.ch). Carbapenemase-producing organisms were not
documented during the study period. As a consequence, third
Figure 1. Selection of patients. Abbreviation: ID, infectious diseases.
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generation cephalosporins were the empirical ﬁrst choice for
non-AmpC-producing Enterobacteriaceae except in previously
known ESBL carriers and in patients with severe sepsis or
neutropenia, where broad spectrum antibiotic treatments were
considered adequate. Fourth generation cephalosporins or
carbapenems were chosen when AmpC-producing Entero-
bacteriaceae were detected. Our local antibiotic policy was
summarized in local consensus guidelines developed by ID
specialists and based on local epidemiology. These guidelines
did not support the use of quinolones as empirical therapy.
Study Deﬁnitions
Polymicrobial bacteremia was deﬁned as the isolation of >1
microorganism during the same bacteremic episode, except
when the second microorganism was a coagulase-negative
staphylococci (generally considered as a contaminant). A pre-
vious ESBL carriage was recorded according to the hospital
infection control database. Immunosuppression included
human immunodeﬁciency virus infection and speciﬁc medica-
tions (prednisone equivalent ≥5 mg/d, cancer chemotherapy,
tumor necrosis factor α inhibitors, and other immunosuppres-
sive drugs). Penicillin allergy was included as stated in the
medical record regardless of stage/gravity of the presumed re-
action. A bacteremia was considered hospital-acquired if blood
cultures were taken ≥48 hours after hospitalization. “Neutrope-
nia” was deﬁned as an absolute neutrophil cell count <0.5 × 109
neutrophils/L. “Severe sepsis” and “septic shock” were deﬁned
according to standard deﬁnitions [12].
Streamlining was deﬁned as the reduction of the antibiotic
spectrum, either after Gram staining or after MALDI-TOF
reporting, as for instance, the interruption of a speciﬁc
anti-gram-positive coverage of vancomycin when only gram-
negative pathogens were seen on the blood culture Gram
stain. Similarly, “spectrum broadening” was deﬁned after 1 of
the 2 steps when the antibiotic coverage changed toward a
broader spectrum. For instance, spectrum broadening oc-
curred following MALDI-TOF reporting of Enterobacter
cloacae, changing empirical therapy from ceftriaxone to cefe-
pime. Gram stain could lead to the introduction of an empiri-
cal antibiotic therapy. MALDI-TOF reporting allowed the
introduction of a focused empirical antibiotic therapy as, for
instance, the introduction of an initial treatment with cefe-
pime in case of the early detection of E. cloacae.
Statistics
Categorical variables were compared using the χ2 or Fisher
exact tests when appropriate; continuous variables were com-
pared using the Mann-Whitney test. Analyses were conducted
using the GraphPad Prism software, version 5.03 (GraphPad
software, San Diego, CA).
RESULTS
General
There were 202 ﬁrst episodes of gram-negative bacteremia
leading to an ID consultation during the study period
(Figure 1), among which 37 (18.3%) were polymicrobial and
120 (59.4%) were hospital-acquired. Main sources of infection
were the digestive tract in 69 cases (34.2%), the urinary tract
in 65 cases (32.2%), and intravascular catheters in 26 cases
(12.9%) (Table 1).
Among the 242 episodes of gram-negative bacteremia that
were excluded as they did not lead to an ID consultation
(Figure 1 and Supplementary Table), 100 (41.3%) were diag-
nosed in the emergency department. Enterobacteriaceae were
the more frequently identiﬁed clade, with 207 episodes (85.5%
of all), among which were 146 cases of E. coli bacteremia.
AmpC-producing bacteria were found in 23 cases (9.5% of all)
and nonfermentative bacteria in 15 cases (6.2%).
Pathogens and Identiﬁcation Scores (Table 2)
Among the 202 episodes of gram-negative bacteremia, 37
(18.3%) were polymicrobial and 165 (81.7%) were monomi-
crobial. Altogether, 143 of 165 episodes of monomicrobial
bacteremia (86.7%) were correctly identiﬁed with a score ≥1.7.
Among the 37 episodes of polymicrobial bacteremia, at least
one pathogen could be reliably identiﬁed at the genus level in
28 cases (75.7%). Nevertheless, a correct identiﬁcation at the
Table 1. Characteristics of the 202 Cases of Gram-negative Bac-
teremia Included in the Study
Characteristics N = 202
Male 122 (60.3)
Age (mean, years) 62
Previous ESBL carriage 4 (2.0)
Immunosuppression 62 (30.7)
Agranulocytosis 9 (4.5)
Severe sepsis/septic shock 28 (13.9)
History of penicillin allergy 11 (5.4)
Hospital-acquired bacteremia 120 (59.4)
ICU acquisition 23 (11.4)
Polymicrobial bacteremia 37 (18.3)
Sources of bacteremia
Digestive tract 69 (34.2)
Urinary tract 65 (32.2)
Catheter infection 26 (12.9)
Respiratory tract 10 (5.0)
Other source 25 (12.4)
Unknown 7 (3.5)
Data are presented as No. (%), unless otherwise indicated.
Abbreviations: ESBL, extended spectrum betalactamase; ICU, intensive care
unit.
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genus level of all pathogens in a given polymicrobial blood
culture was only possible in 11 of 37 cases (29.7%).
Among the 165 episodes of monomicrobial bacteremia, En-
terobacteriaceae were documented in 120 cases (59.4%).
MALDI-TOF identiﬁcation performed on the blood culture
pellet conﬁrmed a high reliability for this bacterial family
since 117 of all Enterobacteriaceae (97.5%) were correctly
identiﬁed with a score ≥1.7. All 27 AmpC-producing Entero-
bacteriaceae species (13.4%) were correctly identiﬁed at the
genus level.
Nonfermentative bacteria were documented in 25 of 202
cases, representing 12.4% of all cases. Pseudomonas spp. were
identiﬁed in 9 of 22 cases (40.9%), whereas the other 3 non-
fermentative bacteria were all correctly identiﬁed at species
level.
Impact of Gram Stain and MALDI-TOF Reporting
The sequential impact of Gram stain and MALDI-TOF identi-
ﬁcation reporting on empirical antibiotic therapy are summa-
rized in Figure 2. Overall, Gram stain reporting had an impact
in 42 cases (20.8% of all 202 gram-negative bacteremia).
Despite a positive impact of Gram stain, MALDI-TOF report-
ing further inﬂuenced the treatment in 8 of 42 cases (19%).
When Gram stain had no impact, MALDI-TOF reporting led
to a modiﬁcation of empirical antibiotic therapy in 63 of 160
cases (39.4%). Altogether, MALDI-TOF identiﬁcation report-
ing had an impact on empirical therapy in 71 cases (35.1% of
all 202 bacteremia cases). The most frequent impact of
MALDI-TOF was an early appropriate broadening of the anti-
microbial spectrum (Table 3). MALDI-TOF identiﬁcation had
an impact on 16 of 27 episodes (59.3%) of monomicrobial
bacteremia caused by AmpC-producing Enterobacteriaceae,
whereas an impact was documented in only 39 of 93 cases
(41.9%) of other Enterobacteriaceae. MALDI-TOF identiﬁca-
tion reporting had an impact in only 8 of 37 episodes (21.6%)
of polymicrobial bacteremia, in only 6 of 25 episodes (24%) of
monomicrobial bacteremia with nonfermentative bacteria and
had no impact in the 4 previously known ESBL carriers.
Impact of Gram stain reporting in cases of polymicrobial bac-
teremia (12 of 37 [32.4%]) was greater than that of MALDI-
TOF MS.
Among the 131 cases where the MALDI-TOF did not lead
to treatment modiﬁcation, an impact would have been possi-
ble in 31 cases but no modiﬁcation occurred. Factors associat-
ed with lack of modiﬁcation of empirical antibiotic therapy
are shown in Table 4. Among these, intensive care unit (ICU)
acquisition of bacteremia was associated with the absence of
consideration of MALDI-TOF result, as were the male sex and
Table 2. Types of Pathogen and Identiﬁcation Scores
Pathogens N = 202 Score > 2 1.7≤ score < 2 Score < 1.7
Enterobacteriaceae 120 (59.4)
Escherichia coli 56 (27.7) 53 3 (…)
Klebsiella spp. 25 (12.4) 18 4 3
Enterobacter spp. 18 (8.9) 15 3 (…)
Citrobacter freundii 1 (0.5) 1 (…) (…)
Citrobacter koseri 4 (2.0) 4 (…) (…)
Serratia spp. 5 (2.5) 5 (…) (…)
Proteus spp. 8 (4.0) 8 (…) (…)
Morganella spp. 2 (1.0) 2 (…) (…)
Hafnia alvei 1 (0.5) (…) 1 (…)
Nonfermentative 25 (12.4)
Pseudomonas spp. 22 (10.9) 5 4 13
Acinetobacter spp. 1 (0.5) 1 (…) (…)
Stenotrophomonas spp. 2 (1.0) 2 (…) (…)
Other aerobic 8 (4.0)
Salmonella spp. 4 (2.0) 2 1 1
Haemophilus spp. 3 (1.5) 1 (…) 2
Campylobacter spp. 1 (0.5) 1 (…) (…)
Anaerobes 12 (5.9)
Bacteroides spp. 7 (3.5) 3 3 1
Other 5 (2.5) (…) 1 4
Polymicrobial (best identification) 37 (18.3) 26 2 9
Data are presented as No. (%) unless otherwise indicated.
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younger age. Adaptation of antibiotic treatment was more
likely for patients presenting with urosepsis (P = .06).
DISCUSSION
In this prospective, single-arm observational study including
202 episodes of gram-negative bloodstream infections, we ob-
served that MALDI-TOF identiﬁcation reporting had an
impact on antibiotic therapy in 35.1% of bacteremia, whereas
Gram stain had an impact in 20.8% of cases. In addition, we
conﬁrmed the excellent reliability of MALDI-TOF for bacterial
identiﬁcation on blood culture pellets outside of validation
studies, [4–6] in the real-life setting of routine microbiology
practice. As previously reported, the reliability of this new
technology was especially high for Enterobacteriaceae [4–6]. A
maximal impact was observed when AmpC-producing Enter-
obacteriaceae were documented, given their particular pattern
of antibiotic resistance. As already published, [4, 13] we docu-
mented a lower reliability of MALDI-TOF in cases of polymi-
crobial bacteremia, a situation where the Gram stain result is
more informative. Thus, this justiﬁes always performing direct
Gram staining examination of any positive blood cultures
even in the MALDI-TOF era.
Reducing the time to result in clinical microbiology has
been achieved using various approaches and aims (1) to
impact on the clinical outcome of patients, (2) to optimize the
use of antibiotics, and (3) to reduce costs [14–17]. Gram stain
reporting is part of routine management of bloodstream infec-
tions, as it has been shown to have the greatest impact on an-
timicrobial empirical therapy [9]. Improvement in Gram stain
turnaround time has even been associated with a decrease in
patient mortality [18]. Indeed, as early appropriate antibiotic
Figure 2. Sequential impact of Gram stain and matrix-assisted laser desorption ionization time-of-ﬂight (MALDI-TOF) identiﬁcation on empirical
antibiotic therapy. Cases that beneﬁted from MALDI-TOF are highlighted in dark gray. Abbreviation: MALDI, matrix-assisted laser desorption ionization.
Table 3. Impact of Sequential Gram Stain and MALDI-TOF
Reporting
Impact of the Sequential Reporting N = 202
Gram stain 42 (20.8)
Streamlining 16 (7.9)
Spectrum broadening 16 (7.9)
Introduction of empirical antibiotic therapy 10 (5.0)
MALDI-TOF MS 71 (35.1)
Streamlining 22 (10.9)
Spectrum broadening 31 (15.3)
Introduction of focused empirical antibiotic therapy 18 (8.9)
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: MALDI-TOF, matrix-assisted laser desorption ionization time-
of-flight; MS, mass spectrometry.
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therapy has been shown to reduce the mortality of bloodstream
infections [19], there is an obvious need for techniques that
could increase initial antibiotic appropriateness. Although
there have been numerous publications in the recent years on
the additional value of bacterial identiﬁcation with MALDI-
TOF in blood cultures [4–6, 13, 20], there are few data on the
clinical impact of this new strategy to justify its implementa-
tion in routine practice. Vlek et al compared 2 sequential
periods in a prospective study: one standard period during
which only Gram staining and results of susceptibility testing
could inﬂuence the antibiotic therapy, and one intervention
period in which MALDI-TOF was added to study its possible
impact on empirical treatment. Among 253 episodes of bacter-
emia, 89 led to MALDI-TOF identiﬁcation with an early
correct identiﬁcation in 56.2% of episodes. The application of
MALDI-TOF increased the proportion of appropriate treat-
ments within 24 hours of blood culture positivity by 11.3% [10].
Hodiamont et al recently presented unpublished data showing
that the addition of MALDI-TOF identiﬁcation to Gram stain
reporting led to an early adaptation of antibiotic therapy in up
to 29% of 73 cases of bloodstream infection [11]. Both studies
came from the Netherlands, where the incidence of antimicro-
bial resistance remains low. Our data from a country with low
but increasing ESBL prevalence are in line with these 2 studies.
Our study has limitations. Its single arm, observational
design precluded us from evaluating the impact of MALDI-
TOF on the clinical outcome of patients as, in our hospital,
MALDI-TOF has been included in the routine management
of blood cultures since we initially validated this approach [5].
We included only those cases managed with the help of an ID
consultation, as these were clinically the most relevant and as
the resulting report allowed us to obtain precise information
regarding the sequence of antibiotic therapy. The overrepre-
sentation of non-AmpC-producing Enterobacteriaceae (mostly
E. coli) in the 242 cases that were excluded and the predomi-
nance of ambulatory cases in that group suggest that, among
these 242 cases, there were more common infections such as
urosepsis, for which the impact of MALDI-TOF identiﬁcation
might be less important and might be managed without the
need of an ID consultation. However, this study design corre-
sponds to the routine clinical management of gram-negative
bacteremia in our hospital and probably in many others. In
this sense, we think that our results are useful to estimate the
true beneﬁts of this new technology in a real-life setting. Our
study was conducted in a low-prevalence area for ESBL and
for multiresistant gram-negative bacteria, which could possibly
lead to an overestimation of the impact of MALDI-TOF MS.
Finally, prescription of an empirical antibiotic therapy is a
complex decision involving epidemiological considerations, se-
verity of disease and experience or education of the clinician
in charge, as suggested by the determinants of the effective
impact of MALDI-TOF MS. The impact of MALDI-TOF may
thus vary according to the epidemiological setting, the site
where bacteremia was managed (particularly ICU) or the pre-
sumed site of infection. Indeed, clinicians might feel more
comfortable with the early identiﬁcation of bacteria using an
unfamiliar technology if the urinary tract was the suspected
source of bacteremia, as uropathogens might be more predict-
able than pathogens from a suspected catheter infection.
Further studies including educational approaches might help
to target these hypotheses.
The main strength of our study is that we document the clini-
cal application of MALDI-TOF performed directly on blood
culture pellets, as well as its successful implementation in
routine clinical microbiology. Indeed, we observed that this new
technology had an impact in more than one-third of all episodes
of gram-negative bacteremia. Although these ﬁndings should be
conﬁrmed by larger, randomized studies including clinical out-
comes, our data suggest that rapid MALDI-TOF MS-based iden-
tiﬁcation of bacteria grown from blood cultures could become a
second critical step in the management of patients with positive
blood cultures besides Gram stain reporting.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online
(http://cid.oxfordjournals.org/). Supplementary materials consist of data
Table 4. Determinants of the Impact of MALDI-TOF on Empirical
Therapy
Characteristics
Impact
(N = 71)
Possible impact
(N = 31)
P
Value
Male sex 45 (63.4) 6 (19.4) <.0001
Age (mean, years) 65.8 61.2 <.0001
Previous ESBL carriage 0 0 NA
Immunosuppression 17 (23.9) 9 (29.0) .63
Agranulocytosis 0 1 (3.2) .30
Severe sepsis/septic
shock
9 (12.7) 3 (9.7) 1.00
History of penicillin allergy 3 (4.2) 2 (6.5) .64
Hospital-acquired
bacteremia
43 (60.6) 22 (71.0) .37
ICU acquisition 1 (1.4) 9 (29.0) <.0001
Polymicrobial bacteremia 8 (11.3) 1 (3.2) .27
Source of bacteremia
Urinary tract 26 (36.6) 5 (16.1) .06
Digestive tract 19 (26.8) 14 (45.2) .11
Catheter infection 12 (16.9) 3 (9.7) .54
Unknown 3 (4.2) 0 .55
Data are No. (%) unless otherwise indicated.
Abbreviations: ESBL, extended spectrum betalactamase; ICU, intensive care
unit; MALDI-TOF, matrix-assisted laser desorption ionization time-of-flight;
NA, not applicable.
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provided by the author that are published to beneﬁt the reader. The
posted materials are not copyedited. The contents of all supplementary
data are the sole responsibility of the authors. Questions or messages re-
garding errors should be addressed to the author.
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